Single-arm, open-label, multicenter, phase II trial Previously untreated stage IV non-clear cell renal cell carcinoma Pembrolizumab + Lenvatinib (n=158

16 Jul

Colorectal Cancer

New Indication: Pembrolizumab for MSI-High Colorectal Cancer

Randomised, open-label, phase 3 study (KEYNOTE-177) Untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer Pembrolizumab 200 mg every 3

15 Mar

Colorectal Cancer

New Indication: Encorafenib, Binimetinib, and Cetuximab for bRAF V600E Mutant Colorectal Cancer

Single-arm, multicenter, Phase-2 trial Previosly untreated, BRAF V600E mutant Colorectal cancer Encorafenib + Binimetinib + Cetuximab q28 (n=95)

15 Mar

Uterine Cancer

New Drug: Dostarlimab for Endometrial Cancer

Multicenter, multicohort, open-abel trial (GARNET) dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen Dostarlimab-gxly q21 (

15 Mar

Breast Cancer

New Indication: Sacituzumab Govitecan for HR+, her2 Negative Breast Cancer

Multicenter, randomized, open-label, phase III Unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer whose disease progressed after a CDK 4/6 inhibit

15 Mar

Prostate Cancer

New Indication: Maintenance Darolutamide for CRPC

Randomized , phase 2 trial Patients with mCRPC who received prior androgen-receptor pathway inhibitors (ARPIs) and subsequently had nonprogressive disease on a taxane Darolutamid

20 Aug

Uterine Cancer

New Protocol: Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma

Single-arm, open-label, multicenter, phase II trial Patients with uLMS, progression on ≥1 prior line treatment Temozolomide +Olaparib (n=22

15 Mar

Bladder Cancer

New Reference: Neoadjuvant CISplatin and Gemcitabine for Urothelial Cancer

Multicenter, single-arm, phase II trial Localized high-grade UTUC or radiographically visible invasive disease Four cycles of split-dose GC (n=57)

15 Mar

Colorectal Cancer

New Protocol: Tucatinib and Trastuzumab for Metastatic Colorectal Cancer

Phase II, open-label, multicenter study Pretreated, HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer Tucatinib + Trastuzumab q21 (n=117)

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries